UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.215

Sortiert nach

Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2)

British journal of pharmacology, 2010-02, Vol.159 (4), p.898-908

2010

Volltextzugriff (PDF)

Environmental and Genetic Factors Affecting Transport of Imatinib by OATP1A2

Clinical pharmacology and therapeutics, 2011-06, Vol.89 (6), p.816-820

2011

Volltextzugriff (PDF)

Associations Between ABCC2 Polymorphisms and Cisplatin Disposition and Efficacy

Clinical pharmacology and therapeutics, 2012-06, Vol.91 (6), p.1022-1026

2012

Volltextzugriff (PDF)

Clinical Pharmacokinetics and Metabolism of Irinotecan (CPT-11)

Clinical cancer research, 2001-08, Vol.7 (8), p.2182-2194

2001

Volltextzugriff (PDF)

Effects of CYP Induction by Rifampicin on Tamoxifen Exposure

Clinical pharmacology and therapeutics, 2012-07, Vol.92 (1), p.62-67

2012

Volltextzugriff (PDF)

Cremophor EL-mediated alteration of paclitaxel distribution in human blood : Clinical pharmacokinetic implications

Cancer research (Chicago, Ill.), 1999-04, Vol.59 (7), p.1454-1457

1999

Volltextzugriff (PDF)

Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies

British journal of cancer, 2010-06, Vol.102 (12), p.1699-1706

2010

Volltextzugriff (PDF)

Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38

British journal of cancer, 2002-07, Vol.87 (2), p.144-150

2002

Volltextzugriff (PDF)

A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors

Annals of oncology, 2006-08, Vol.17 (8), p.1320-1327

2006

Volltextzugriff (PDF)

Irinotecan (CPT-11) metabolism and disposition in cancer patients

Clinical cancer research, 1998-11, Vol.4 (11), p.2747-2754

1998

Volltextzugriff (PDF)

Body-Surface Area–Based Dosing Does Not Increase Accuracy of Predicting Cisplatin Exposure

Journal of clinical oncology, 2001-09, Vol.19 (17), p.3733-3739

2001

Volltextzugriff (PDF)

Elongated Multiple Electronic Cascade and Cyclization Spacer Systems in Activatible Anticancer Prodrugs for Enhanced Drug Release

Journal of organic chemistry, 2001-12, Vol.66 (26), p.8815-8830

2001

Volltextzugriff (PDF)

Factors affecting pharmacokinetic variability of oral topotecan: a population analysis

British journal of cancer, 2004-01, Vol.90 (2), p.343-347

2004

Volltextzugriff (PDF)

Real-time pharmacokinetics guiding clinical decisions: phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumours

European journal of cancer (1990), 2004-03, Vol.40 (5), p.681-688

2004

Volltextzugriff (PDF)

Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo

Clinical cancer research, 1998-08, Vol.4 (8), p.1937-1942

1998

Volltextzugriff (PDF)

Modulation of camptothecin analogs in the treatment of cancer: a review

Anti-cancer drugs, 2001-02, Vol.12 (2), p.89-105

2001

Volltextzugriff (PDF)

Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors

Journal of clinical oncology, 1997-03, Vol.15 (3), p.1087-1093

1997

Volltextzugriff (PDF)

Pharmacological effects of formulation vehicles: Implications for cancer chemotherapy

Clinical pharmacokinetics, 2003-01, Vol.42 (7), p.665-685

2003

Volltextzugriff (PDF)

Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line

British journal of cancer, 1998-05, Vol.77 (10), p.1645-1652

1998

Volltextzugriff (PDF)

A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors

Cancer chemotherapy and pharmacology, 2006-11, Vol.58 (5), p.673-680

2006

Volltextzugriff (PDF)

Phase I pharmacokinetic and sequence finding study of the combination of docetaxel and methotrexate in patients with solid tumours

European journal of cancer (1990), 2002-03, Vol.38 (4), p.497-504

2002

Volltextzugriff (PDF)

Inter- and Intrapatient Variability in Oral Topotecan Pharmacokinetics: Implications for Body-Surface Area Dosage Regimens

Clinical cancer research, 2000-07, Vol.6 (7), p.2685-2689

2000

Volltextzugriff (PDF)

Phase I Pharmacologic Study of Oral Topotecan and Intravenous Cisplatin: Sequence-Dependent Hematologic Side Effects

Journal of clinical oncology, 2000-05, Vol.18 (10), p.2104-2115

2000

Volltextzugriff (PDF)

A Comparison of Clinical Pharmacodynamics of Different Administration Schedules of Oral Topotecan (Hycamtin)

Clinical cancer research, 1999-01, Vol.5 (1), p.69-75

1999

Volltextzugriff (PDF)

Modulation of cisplatin pharmacodynamics by Cremophor EL: experimental and clinical studies

European journal of cancer (1990), 2002-01, Vol.38 (1), p.205-213

2002

Volltextzugriff (PDF)

1 – 25 von 1.215

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.061)
Mit Volltextzugriff
(1.016)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Nature Genetics
(56)
Fluid Phase Equilibria
(35)
Nature
(35)
Nature Communications
(32)
Physical Review. D, Particles And Fields
(32)
Physical Review Letters
(28)
Journal Of Thoracic Disease
(21)
Plos Genetics
(20)
Journal Of Chemical And Engineering Data
(19)
Journal Of Clinical Oncology
(18)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2)

Environmental and Genetic Factors Affecting Transport of Imatinib by OATP1A2

Associations Between ABCC2 Polymorphisms and Cisplatin Disposition and Efficacy

Clinical Pharmacokinetics and Metabolism of Irinotecan (CPT-11)

Effects of CYP Induction by Rifampicin on Tamoxifen Exposure

Cremophor EL-mediated alteration of paclitaxel distribution in human blood : Clinical pharmacokinetic implications

Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies

Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38

A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors

Irinotecan (CPT-11) metabolism and disposition in cancer patients

Body-Surface Area–Based Dosing Does Not Increase Accuracy of Predicting Cisplatin Exposure

Elongated Multiple Electronic Cascade and Cyclization Spacer Systems in Activatible Anticancer Prodrugs for Enhanced Drug Release

Factors affecting pharmacokinetic variability of oral topotecan: a population analysis

Real-time pharmacokinetics guiding clinical decisions: phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumours

Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo

Modulation of camptothecin analogs in the treatment of cancer: a review

Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors

Pharmacological effects of formulation vehicles: Implications for cancer chemotherapy

Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line

A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors

Phase I pharmacokinetic and sequence finding study of the combination of docetaxel and methotrexate in patients with solid tumours

Inter- and Intrapatient Variability in Oral Topotecan Pharmacokinetics: Implications for Body-Surface Area Dosage Regimens

Phase I Pharmacologic Study of Oral Topotecan and Intravenous Cisplatin: Sequence-Dependent Hematologic Side Effects

A Comparison of Clinical Pharmacodynamics of Different Administration Schedules of Oral Topotecan (Hycamtin)

Modulation of cisplatin pharmacodynamics by Cremophor EL: experimental and clinical studies

Suchergebnisse filtern